Skip to search formSkip to main contentSkip to account menu

Loss of Chromosome 17p

Known as: 17p Deletion, del(17p) 
A cytogenetic abnormality that refers to the allelic loss of all or part of the short arm of chromosome 17.
National Institutes of Health

Related topics

Related topics

50 relations
Advanced Pleural Malignant MesotheliomaAlcohol-Related Hepatocellular CarcinomaBCLC Stage 0 Hepatocellular CarcinomaBCLC Stage C Hepatocellular Carcinoma

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Meta-analysis of the efficacy of treatments for newly diagnosed and relapsed/refractory multiple myeloma with del(17p)
We analyzed the treatment of newly diagnosed and relapsed/refractory multiple myeloma (NDMM/RRMM) patients with del(17p… 
2014
2014
Integration of Ex Vivo Drug Testing and in-Depth Molecular Profiling Reveals Oncogenic Signaling Pathways and Novel Therapeutic Strategies for Multiple Myeloma
![Graphic][1] Introduction New drugs have improved survival for multiple myeloma (MM) patients, however, patient outcome… 
2013
2013
[Clinical and laboratory features of four cases with IgM multiple myeloma].
OBJECTIVE To improve the understanding of the clinical and laboratory features of the IgM multiple myeloma (MM). METHODS The… 
2011
2011
results of the German CLL Study Group CLL3X trial poor-risk chronic lymphocytic leukemia: long-term clinical and MRD Allogeneic stem cell transplantation provides durable disease control in
the German CLL Study Group Zenz, Dirk Winkler, Michael Hallek, Michael Kneba, Norbert Schmitz, Stephan Stilgenbauer and for Zeis… 
2008
2008
The clinical significance of chromosome 17p deletion in chronic lymphocytic leukemia: A study of 180 consecutive patients
7035 Background: Preliminary data indicate that the presence of chromosome 17p deletion (17p-) by fluorescent in-situ… 
2006
2006
The effect of IgVH mutational status on the induction of apoptosis by rituximab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: evidence from a clinical phase I/II trial.
We investigated tumor cell apoptosis in vivo in 14 heavily pretreated patients with B-cell chronic lymphocytic leukemia… 
2006
2006
Select high risk genetic features predict earlier progression following chemotherapy in chronic lymphocytic leukemia: Prospective randomized trial (Intergroup E2997) to evaluate justification for…
6521 Background: Genomic features including lack of IgVH mutations, del(11q), del(17p), and p53 mutations have been reported to… 
2004
2004
Critical Molecular Studies to Strategically Plan Therapy in Chronic Lymphocytic Leukemia (CLL): Correlating Cellular Proteins with Defined Prognostic Patient Subsets and Their Response to Treatment.
The critical importance of specific proteins including Bcl-2, Mcl-1, XIAP, Bax, Caspase-3, Traf-1, and ZAP70 in predicting… 
Review
2002
Review
2002
FLT 3 inhibition as tailored therapy for acute myeloid leukemia
dum-Nielsen K. Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by… 
Review
1992
Review
1992
Suppressor genes in breast cancer: an overview.
It is apparent that multiple genetic events occur in the development and progression of breast cancer. From the limited data… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)